Navigation Links
Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/19/2008

PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that it has cancelled its corporate presentation planned for today at the Lazard Capital Markets 5th Annual Healthcare Conference due to the proximity of the release of preliminary top-line data from the first Phase III pivotal clinical trial of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

The company anticipates that it will release the preliminary top-line data within the next week.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains a forward-looking statement related to the timing of the release of clinical results related to Jazz Pharmaceuticals' JZP-6 product candidate for the treatment of fibromyalgia. This forward-looking statement is based on the company's current expectations and inherently involves significant risks and uncertainties. The actual timing of the release of clinical results could differ from that anticipated in such forward-looking statement as a result of these risks and uncertainties. Risk factors related to Jazz Pharmaceuticals' clinical trials are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 14, 2008.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MiddleBrook Pharmaceuticals Hires Key Commercial Team Members
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... May 5 PLC Systems Inc.,(Amex: PLC ) announced ... its,financial results for the first quarter ended March 31, 2008 ... plans to host a,conference call to discuss those results at ... may be joined via telephone by dialing (800) 638-4930 or ...
... N.J., May 5 Eisai Corporation of North,America ... as,President of Eisai Inc. In her new role, ... Eisai Inc., the U.S. commercial,operation of Eisai Co., ... a strong track record of building,high-performing organizations that ...
... May 5 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,("Lorus") ... dedicated in,the research, development and commercialization of ... cancer, announced today that it has,strengthened its ... Dr. Saeid,Babaei to Vice-President of Business Development ...
Cached Biology Technology:PLC Systems to Host First Quarter Conference Call on May 15, 2008 2Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc. 2Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 2Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 3Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 4
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... LONDON , April 27, 2010 Dominio Amigo S.A.S ... the .CO domain name launch. , , ... Julio Camacho , CEO, Dominio Amigo S.A.S , ... have consistently performed,at both ccTLD and gTLD launches, securing the very best Internet ...
... LONDON , April 27, 2010 ... backdrop. In,a video interview with online financial broadcaster http://www.cantos.com ,Chief Executive ... which,demonstrates the resilience of our business and the success of our enhanced,focus ... ...
... , April 27 The PMI Group, Inc. (NYSE: ... sell in concurrent underwritten public offerings an aggregate of 77,765,000 shares ... $6.15 per share and $261 million aggregate ... connection with the offerings, PMI has granted the underwriters 30-day options ...
Cached Biology News:Dominio Amigo Announce Domainmonster as .CO Technical Partner 2Dominio Amigo Announce Domainmonster as .CO Technical Partner 3Imperial Tobacco - 2010 Half Year Results Interviews 2The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 2The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 3The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 4
... Precision-designed for Optimal Microdissection , CapSure ... the precise and rapid extraction of populations ... cytology samples with Laser Capture Microdissection., ... Downstream Molecular Analysis , All CapSure LCM ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... ChipReader systems are highly sensitive laser confocal ... These are advanced scanners that meet your ... background level, and optimizing the signal on ... end of the range for increased sensitivity. ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
Biology Products: